Spitzer A, et al. Intra-articular injection of an extended-release formulation of triamcinolone acetonide provided significant improvement in pain, stiffness and function in patients with knee osteoarthritis. Presented as an oral at the AAHKS Annual Meeting, Friday, November 11, 2016. Paper #8.
Conaghan P, et al. Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study. Osteoarthritis Cartilage. 2016; 24:S49-S50. Abstract 70.
Bodick N, et al. Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2015; 23:A82-A416. Abstract 591.
Bodick N, et al. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J Bone Joint Surg Am. 2015; 97(11):877-88.
Bodick N, et al. A randomized, double-blind, dose ranging study comparing FX006, an intra-articular sustained-release formulation of triamcinolone acetonide, to an approved injectable suspension of TCA in patients with osteoarthritis of the knee. Arthritis Rheumatol. 2013; 65(10): S1138. Abstract 2668.